OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Signum Biosciences, Inc.

3 Projects | 1 Researchers | $519,000 Invested

2011

Signum Biosciences, Inc.

Steven Braithwaite, PhD

Phosphoprotein phosphatase 2A (PP2A): A novel therapeutic target for Alzheimer's disease; For Clinical Development of SIG1012

  • Funding Amount: $100,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Status: Closed

2010

Signum Biosciences, Inc.

Steven Braithwaite, PhD

Phosphoprotein phosphatase 2A (PP2A): A novel therapeutic target for Alzheimer's disease; For Clinical Development of SIG1012

  • Funding Amount: $150,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Status: Closed

2009

Signum Biosciences, Inc.

Steven Braithwaite, PhD

Phosphoprotein phosphatase 2A (PP2A): A novel therapeutic target for Alzheimer's disease

  • Funding Amount: $269,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Status: Closed